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© 2013 The Japan Society of Histochemistry andKeratinocyte growth factor (KGF) is considered to be one of the most important mitogens
for lung epithelial cells. The objectives of this study were to confirm the effectiveness of
intratracheal injection of recombinant human KGF (rhKGF) during compensatory lung growth
and to optimize the instillation protocol. Here, trilobectomy in adult rat was performed, followed
by intratracheal rhKGF instillation with low (0.4 mg/kg) and high (4 mg/kg) doses at various
time-points. The proliferation of alveolar cells was assessed by the immunostaining for
proliferating cell nuclear antigen (PCNA) in the residual lung. We also investigated other
immunohistochemical parameters such as KGF, KGF receptor and surfactant protein A as
well as terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Con-
sequently, intratracheal single injection of rhKGF in high dose group significantly increased
PCNA labeling index (LI) of alveolar cells in the remaining lung. Surprisingly, there was no
difference in PCNA LI between low and high doses of rhKGF with daily injection, and PCNA
LI reached a plateau level with 2 days-consecutive administration (about 60%). Our results
indicate that even at low dose, daily intratracheal injection is effective to maintain high
proliferative states during the early phase of compensatory lung growth.
Key words: recombinant human KGF, intratracheal injection, compensatory growth, trilobectomy, 
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I. Introduction
Chronic obstructive pulmonary disease (COPD), in-
cluding emphysema, is increasing, and by 2020 will be the
third leading cause of death worldwide. COPD patients tend
to merge lung cancer. Especially, patients of combined
pulmonary fibrosis and emphysema syndrome have a high
prevalence of lung cancer [11]. However, the high rates of
morbidity and mortality are actually associated with their
lower forced expiration volume in one second. Therefore,
development of effective therapies to promote lung regen-
eration is critically needed.
Because of the structural complexities, lung regenera-
tion has been known to be difficult, compared to that of
liver, neuron or skin. On the other hand, compensatory lung
growth after lung injury or surgical resection was reported
in the previous papers [5, 9, 24]. Although the compen-
satory lung growth is a transient event and cannot be
continued for a long time, it should have a possibility to
prevent the decline of lung function or maintain the function
after lung resection. The growth process in compensatory
lung growth involves increasing lung volume, weight, cell
proliferation, and pulmonary function. In fact, it has been
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reported previously that many pathways are involved in the
compensatory lung growth [8, 10, 19], and they seem to be
interacted mutually making the situations complicated.
Eventually, there remain many hurdles to be considered for
the application to clinical therapy.
Rubin and colleagues discovered keratinocyte growth
factor (KGF) as a mesenchymal cell–derived epithelial cell
mitogen [18], and subsequently KGF receptor (KGFR; bek
IIIb) was identified in various epithelial cells [7]. KGF has
been reported as a pleiotropic growth factor with morpho-
genic, motogenic, tumorgenesis and anti-apoptotic proper-
ties in the lung [16, 17, 20, 23, 26]. KGF mainly stimulated
proliferation and function of lung alveolar type II cells [6],
but also promoted the regeneration of tracheal cartilages in
rodents [1].
For recovery of pulmonary function in damaged lung,
the increase of surface area of alveoli should be essential to
maintain the abilities of gas exchange. Alveolar surface area
is covered by alveolar type I cells predominantly, which are
terminally differentiated from alveolar type II cells. Hyper-
plasia of alveolar epithelial type II after instillation of
recombinant human KGF (rhKGF) leads to terminal dif-
ferentiation to alveolar type I cells [6]. KGF expression
is upregulated in rodent models of lung injury and has
been implicated in the induction of alveolar epithelial cell
proliferation [4]. Ulich et al. reported the progression of
alveolar cell type II hyperplasia in the normal adult rat lung
at 72 hr after intratracheal KGF administration [23]. Kaza
and associates demonstrated that intraperitoneal administra-
tion of KGF enhanced compensatory lung growth after
postpneumonectomy through alveolar proliferation until 21
days after operation [10]. This means that alveolar cell
proliferation by KGF instillation would be logically impor-
tant for pulmonary function. But the effect of the direct
administration of rhKGF at early phase of compensatory
lung growth was still unclear. Later, we confirmed the
involvement of KGF and KGFR in the compensatory lung
growth and then the usefulness of gene therapy using KGF
expression vector to accelerate it after lung resection [12].
The gene therapy seemed to be suitable for short-term
acceleration of lung compensatory growth, but could cause
some complication including pneumothorax and pulmonary
bleeding.
In the present study, we examined a direct and short-
term effect of intratracheal administration of rhKGF on
alveolar cell proliferation as well as on the expression of
KGFR during lung compensatory growth after trilobectomy
in rats. As a result, we found a dramatic increase in the
number of proliferating alveolar cells and pleural cells, and
defined the optimal protocol to administer rhKGF to accel-
erate lung compensatory growth.
II. Materials and Methods
Animals, surgical procedure and tissue preparation
Pathogen-free 8-weeks-old male Lewis rats weigh-
ing 280–320 g were purchased from Charles River Japan
(Kanagawa, Japan). Each experimental group consisted of
three or four rats at each given time-points. Rats were anes-
thetized with intraperitoneal injection of 25 mg/kg sodium
pentobarbital (Dainippon Sumitomo Pharma, Osaka,
Japan), and then underwent a right posterolateral thoracot-
omy. The right lung of rats consisted of 4 lobes; the cranial,
middle, accessory and caudal lobes were freed from the
inferior pulmonary ligament. Three lobes (cranial, middle
and accessory lobe) were excised as previously described
[12]. The remaining caudal lobe after trilobectomy was used
for the following investigation after fixed in 4% paraform-
aldehyde in PBS (pH 7.4) (Merck, Darmstadt, Germany)
and embedded in paraffin. Serial 5-µm sections were cut,
and each specimen was stained with hematoxylin and
eosin. All animal experiments were performed in accord-
ance with National Institutes of Health guidelines dictated
by the Animal Care Facility at Nagasaki University Gradu-
ate School of Medicine (approval code 0708100614).
Administration of KGF protein
Recombinant human KGF protein (Amgen, Thousand
Oaks, CA) was administered intratracheally after the oper-
ation. According to our previous results, the proliferating
cell nuclear antigen labeling index (PCNA-LI) was
1.74%±0.75% at day 0 and increased significantly at day 2
and reached a maximum (8.49±1.83%) at day 4 after
trilobectomy [12]. And then the PCNA-LI returned to the
control level at day 14. For titration of rhKGF, rats were
divided into three groups (PBS alone, 0.4 mg KGF/kg body
weight (BW) and 4 mg KGF/kg BW), and each group was
administered with PBS alone or KGF at 48 hr after opera-
tion (Table 1). They were sacrificed 96 hr after operation
and analyzed. For the experiment with daily injections of
rhKGF, rats were divided into three groups as described
above and each group was further subdivided into three
groups by times of injection (one day, two days and three
days injection) (Table 1).
Immunohistochemistry of KGF, KGFR and surfactant 
protein A (SP-A) in the lung
Immunohistochemistry was performed to determine
the expression of KGF and KGFR in tissue sections
using anti-KGF and anti-KGFR antibodies as previously
described [2, 15, 22, 26]. Sections of rat lung tissue were
deparaffinized and those for KGFR expression were pre-
treated with 0.2% Triton X-100 in PBS for 15 min at RT.
Endogenous peroxidase activity was inactivated with 0.3%
H2O2 in methanol, and the sections were preincubated with
500 µg/ml normal goat IgG in 1% BSA in PBS to block
nonspecific reaction with the first antibody. The sections
were then incubated for 2 hr with primary antibody at 1.0
µg/ml for the anti-KGF antibody, 1 : 600 for anti-KGFR
antiserum and 1 : 30 for the anti-SP-A antibody (Santa Cruz
Biotechnology, Santa Cruz, CA), and then incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (1 : 100) (MBL, Nagoya, Japan) for KGF, KGFR and
SP-A for 1 hr as a secondary antibody. HRP sites were
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visualized by treatment with 3,3'-diaminobenzidine-4HCl
(DAB; Dojindo, Kumamoto, Japan) and H2O2.
Terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) Staining
To analyze internucleosomal DNA fragmentation as a
hallmark of apoptosis, TUNEL was performed as previ-
ously described [2, 3]. The sections were reacted with 200
U/ml TdT (Roche, Munich, Germany) dissolved in TdT
buffer (25 mM Tris/HCl buffer, pH 6.6, containing 0.2 M
potassium cacodylate and 0.25 mg/ml BSA) (Roche,
Munich, Germany) supplemented with 0.5 µM biotin-16-
dUTP, 20 µM dATP, 1.5 mM CoCl2, and 0.1 mM dithio-
threitol for 90 min at 37°C. The reaction was terminated
by washing with 50 mM Tris-HCl buffer (pH 7.4) and
the sections were reacted with HRP-goat anti-biotin anti-
body (1 : 100, diluted with 5% BSA in PBS) (Vector,
Burlingame, CA). The HRP sites were visualized with
DAB and H2O2 in the presence of nickel and cobalt ions [2].
Evaluation of proliferating activity of lung cells
Lung cell proliferation was analyzed immunohisto-
chemically using an anti-PCNA antibody (DAKO, Glostrup,
Denmark) according to the previous paper [1, 2, 12].
Briefly, the sections were autoclaved and incubated with
anti-PCNA antibody (1 : 100) as the primary antibody and
HRP-goat anti-mouse IgG (1 : 100) (Chemicon Interna-
tional Temecula, CA) as the secondary antibody. Negative
control sections were incubated with normal mouse IgG in
place of primary antibody.
Quantitative analysis of PCNA positive cells
PCNA LI was measured according to the previous
paper [1, 12, 21]. Briefly, PCNA staining was graded as
positive or negative, compared to the negative control. For
each section, more than 2,000 cell nuclei were counted over
randomly selected fields at 400× magnification. The num-
ber of positive cells was expressed as the percentage of cells
with positive nuclei per total number of counted nuclei. This
method avoided counting error due to cell size.
Statistical analysis
Data were expressed as mean±SEM. Values of dif-
ferent groups were compared using one-way analysis of
variance. For statistical analysis, we used the unpaired
Student’s t test and a P value of <0.05 was considered
statistically. All statistical analyses were performed using
JMP software (SAS, Cary, NC).
III. Results
Effect of rhKGF administration on histological and 
histochemical characters in the remnant lung during 
compensatory growth after trilobectomy
First, we examined the effect of intratracheal adminis-
tration of rhKGF at a dose of 0.4 mg/kg BW on histology
of the growing lung at 48 hr after trilobectomy. As shown
in Fig. 1A and 1E, the rhKGF administration markedly
increased the thickness of pleura and alveolar septum of the
remnant lung, compared to the control group with PBS
alone. In accordance with the histological finding, the
expression of KGFR was much more widely induced in
both alveolar and pleural cells (Fig. 1F), while a few
significant increase in KGFR positive cells was detected in
the control lung with PBS alone (Fig. 1B). The number of
KGF positive cells was also clearly increased in alveolar
and pleural parts although the origin of KGF, i.e., rat KGF
or rhKGF was not discriminated in the present study
(Fig. 1C and 1G). Similarly, PCNA positive cells were
more abundant in both parts of the remnant lung with
Table 1. Protocol for single injection (A) and for daily injections (B)
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rhKGF administration (Fig. 1H), compared to the control
(Fig. 1D).
Moreover, SP-A expression was increased by rhKGF,
especially in the pleural area (Fig. 2A and 2C), indicating
the promotion of the function of type II alveolar cells.
In addition, there was no change in TUNEL positive cell
population in the presence or absence of the extraneous
rhKGF (Fig. 2B and 2D).
Effect of single administration with different doses of 
exogenous rhKGF on alveolar cell proliferation
To explore an optimal condition of rhKGF admin-
istration, the effect of low and high doses of rhKGF on
alveolar cell proliferation was investigated by PCNA LI.
As shown in Fig. 3A, PCNA positive cells were found in
the remnant lung after trilobectomy without rhKGF admin-
istration, where the PCNA LI was 14.9±6.47% for alveolar
epithelial cells. On the other hand, single intratracheal ad-
ministration of rhKGF after trilobectomy markedly increased
PCNA positive alveolar epithelial cells, as shown in Fig. 3B
and 3C. Very interestingly, the size of alveolar cells was
markedly enlarged at the same time. To analyze quan-
titatively, PCNA LI was measured at 48 hr after single
administration of PBS alone or rhKGF (Fig. 4). In PBS
group, PCNA LI was not significantly changed, compared
to the sham control (without injection 14.9±6.4%, PBS
21.1±5.9%, p=0.27). In rhKGF injected groups, PCNA LI
was significantly increased dose-dependently; the LI in
4 mg/kg KGF group was significantly higher than that of
0.4 mg/kg KGF group (61.9±6.31% vs. 46.3±6.8% respec-
tively, p=0.017).
Effect of consecutive daily administrations with rhKGF 
on alveolar cell proliferation
Finally, we examined the effectiveness of daily admin-
istrations with rhKGF on alveolar epithelial cell prolif-
eration with different timings and doses, as described in
Table 1. Histological examination revealed that the daily
application of rhKGF enhanced thickening of alveolus and
pleural region more effectively (Fig. 3D). Surprisingly,
there was no significant difference in PCNA LI between
low and high doses of rhKGF at any time-tables, as shown
in Fig. 5. Furthermore, the maximal level of PCNA LI
Fig. 1. Effect of rhKGF administration on the compensatory growth of remnant lung after trilobectomy. The rats were treated with PBS (A–D)
or rhKGF (E–H) at 48 hr after trilobectomy and sacrificed 48 hr later. Histological examination was done with hematoxylin-eosin staining (A,
E). The expression of KGF (B, F), KGFR (C, G) and PCNA (D, H) was examined immunohistochemically. Magnification; ×40 (Bar=500 µm).
Fig. 2. Effect to SP-A expression and apoptosis by rhKGF adminis-
tration on the compensatory growth of remnant lung after trilobec-
tomy. The rats were treated with PBS (A, B) or rhKGF (C, D) at
48 hr after trilobectomy and sacrificed 48 hr later. The remaining
lungs were analyzed for the expression of SP-A (A, C) and TUNEL
(B, D). Magnification; ×40 (Bar=500 µm).
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Fig. 3. Immunostaining for PCNA in the remnant lung administrated with rhKGF in various experimental conditions. The remnant lungs treated
with PBS (A), 0.4 mg/kg KGF with a single injection (B), 4 mg/kg KGF with a single injection (C), and 4 mg/kg KGF with consecutive 3 days
injection (D) were analyzed for the expression of PCNA immunohistochemically. Magnification; ×200 (Bar=100 µm).
Fig. 4. Effect of single injection with different doses of rhKGF on
alveolar cell proliferation after trilobectomy. Dose-dependent
changes in PCNA LI were analyzed in the remnant lung with a
single intratracheal injection of PBS or rhKGF. There was a sig-
nificant difference between 0.4 mg/kg KGF and 4 mg/kg KGF
(46.3±6.8% vs. 61.9±6.31% respectively, p=0.017). *P<0.05.
Fig. 5. Effect of daily injections with different doses of rhKGF
on alveolar cell proliferation after trilobectomy. Dose-dependent
changes in PCNA LI were analyzed in the remnant lung with daily
intratracheal injection of PBS or rhKGF. There was a significant
change between day 1 and day 2 in the groups of 0.4 mg/kg KGF
and 4 mg/kg KGF (0.4 mg/kg; 33.2±5.6, 55.6±9.38% respectively,
p=0.003, 4 mg/kg; 24.2±3.77, 56.3±6.6%, respectively, p=0.002).
PCNA LI reached a plateau level with two days-injection. There
was no significant difference between 0.4 mg/kg KGF and 4 mg/kg
KGF at any time-points. *P<0.05.
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seemed to be about 60% in any administration protocols
used here. Therefore, 2–3 days consecutive administrations
with the low dose of rhKGF were enough to attain the
maximum value of PCNA LI even at 72 hr after operation.
IV. Discussion
In the present study, we investigated a possibility of
intratracheal injection of rhKGF to promote the com-
pensatory lung growth after trilobectomy. Acceleration in
alveolar cell proliferation without any effect on apoptosis
indicated that rhKGF may be a novel drug to be used for
intratracheal therapy for improvement of pulmonary func-
tion after lung resection. Importantly, we found that even
small amount of KGF was enough to support a maximal
proliferation of alveolar epithelial cells during compensa-
tory lung growth with daily administration protocol. Fur-
thermore, the increase in SP-A expression by KGF strongly
suggested that rhKGF affected alveolar type II cells effec-
tively. Interestingly, intratracheally injected KGF seemed to
exert its effect throughout a whole remnant lung since the
increase in pleural cell proliferation and pleural thickness
was occurred.
Compensatory lung growth after lung resection has
been actively investigated and it should be noted that many
factors were implicated in the events. For example, retinoid
acid enhanced lung growth after pneumonectomy in rats
[9]. Basic fibroblast growth factor induced an increase
in pulmonary blood flow in the damaged canine lung
[13]. Hepatocyte growth factor was reported to be a potent
mitogen for rat alveolar type II cells and might work
simultaneously on various types of cells [19]. Moreover, it
was reported that epidermal growth factor stimulates the
differentiation of alveolar type II cells and biosynthesis of
surfactant precursor proteins [8], and the expression of
vascular endothelial growth factor was up-regulated by the
stimulus for alveolarization [14]. However, it is still too
complicated to explain the total story. Now KGF is con-
sidered as one of the most important growth factors in
this situation [10, 12].
Kaza et al. reported that weekly intraperitoneal admin-
istrations of 21 mg KGF/kg BW enhanced compensatory
lung growth after postpneumonectomy through alveolar
proliferation until 21 days after operation, while no induc-
tion of alveolar cell proliferation, even though with KGF
administration, was found in sham-operated rats [10]. On
the other hand, Ulich and Fehrenbach reported that prolif-
eration of lung epithelial cells was induced 2 or 3 days after
intratracheal injection of 5 mg/kg KGF in normal adult rat
lung [6, 23]. The major differences between these experi-
ments are routes and doses for the drug administration. The
former administrated 21 mg/kg KGF intraperitoneally, but
the latter gave only 5 mg/kg KGF intratracheally. Neverthe-
less, the latter protocol seemed more effective for alveolar
cell proliferation. Recently, we have shown the usefulness
of gene therapy using KGF expression vector for lung
compensatory growth after lung resection [12]. However,
this gene therapy method has some difficulty to use
especially in direct transfection into lung. In clinical prac-
tice, complications including pneumothorax or hemothorax
should arise remarkably by the method [25]. Therefore, in
this study, we chose intratracheal injection of rhKGF to
evaluate short term protocols for acceleration of alveolar
cell proliferation after trilobectomy.
Ulich et al. reported that a single intratracheal injection
of KGF caused a prominent dose-dependent proliferation of
alveolar cells; a substantial increase of alveolar cells was
found at 5.0 and 10.0 mg/kg KGF and a mild increase was
found at 1.0 mg/kg KGF in normal adult rat lung [23]. With
rat compensatory lung growth model, we confirmed that a
single intratracheal administration of rhKGF induced alve-
olar cell proliferation significantly and dose-dependently.
To our surprise, however, daily administrations of KGF
could induce the maximal level of increase of alveolar
epithelial cells even at the low dose (0.4 mg KGF/kg BW)
after trilobectomy. Moreover, our previous study revealed
that PCNA LI reached a maximum at day 4 after trilobec-
tomy [12], indicating that the daily administration of rhKGF
accelerated to reach the maximal PCNA LI from day 4 to
day 3 after trilobectomy. Based upon these results, we
concluded that two days of intratracheal injection with
rhKGF are enough to promote compensatory lung growth
effectively. Considering that KGF acts to prevent cells from
apoptosis, these results indicate that daily administration of
rhKGF during compensatory lung growth after lung resec-
tion could lead to continuous proliferation of alveolar cells
and pleural cells, and there is a possibility of further
administration to give rise quick recovery of pulmonary
function after lung resection.
Intratracheal drug administration by using nebulizer is
often used as a simple and convenient medical examination
for expectorant clinically. Therefore, we believe that rhKGF
has a potential as a key drug that can promote compensatory
lung growth after lung resection, although further studies
are needed to clarify the effect of intratracheal rhKGF
administration on a variety of respiratory functions in
compensatory lung growth.
In conclusion, our results clearly demonstrated that the
protocol with daily intratracheal administration of rhKGF
can promote the compensatory lung growth significantly
even at a low dose. We believe that the findings in this study
would be useful to develop a new instillation therapy with
KGF and other growth factors for the promotion of lung
compensatory growth.
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